China Becomes 6th Country to Approve Edaravone Infusion Therapy for ALS
People in China with amyotrophic lateral sclerosis (ALS) can now access edaravone (brand names Radicava, Radicut, among others), following its approval by the National Medical Products Administration, the country’s regulatory agency. The infusion therapy (delivered into the veins) is meant to slow ALS progression and will…